Tuesday, January 16, 2018 – The FDA expanded approval of Gilotrif (afatinib), a first-line treatment for patients with non-small cell lung carcinoma (NSCLC) that is epidermal growth factor receptor (EGFR) mutation-positive. Patients with lung cancers with EGFR S768I, L861Q and G719X may now take Gilotrif.
Gilotrif, an oral, once-daily EGFR-directed therapy developed by Boehringer Ingelheim, is currently approved in the U.S. to treat people with NSCLC that has certain EGFR gene changes, has spread to other parts of the body (metastatic) and has been previously treated for metastatic lung cancer.
“This approval is more welcome news for our lung cancer community. These types of advances are helping expand access to treatment options for patients who might benefit from targeted therapies to fight their specific type of lung cancer” said Laurie Fenton Ambrose, President and CEO of Lung Cancer Alliance.
Click here for more information about this announcement.